|Description||Venture Capital Firm|
|Lumira Capital ll, 3/2012||$100M|
|Merck Lumira Biosciences Fund, 3/2012||$50M|
|Lumira Capital II, 11/2013||C$10M|
Built on a foundation that leverages over 20 years of North American venture capital experience, the Lumira Capital team has substantial experience helping to build transformational health and life science companies.
Our goal is to make investments in market leading companies and work in partnership with those companies to develop and implement strategies to build significant businesses that in turn allow us to generate profitable exits that maximize returns within a reasonable time frame.
As partners in our businesses we are committed to the success of our portfolio companies. We roll up our sleeves and work side by side with our entrepreneurs, their management teams and our syndication partners – leveraging our internal resources, knowledge networks, deep industry expertise and relationships, as well as our operational and leadership experience to help the businesses achieve their full potential.
|Aurinia Pharmaceuticals||2/2014||Post IPO Equity||$52M||9|
|DC Devices||3/2013||Series A||$10.7M||3|
|Argos Therapeutics||4/2012||Series D||$25M||5|